These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35789506)

  • 1. Reply to 'development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani F et al.
    Falcinelli F; Lamberti A; Cota C; Rubegni P; Cinotti E
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e976-e978. PubMed ID: 35789506
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to 'Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani et al.
    Martora F; Fabbrocini G; Nappa P; Megna M
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):e750-e751. PubMed ID: 35679165
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2.
    Solimani F; Mansour Y; Didona D; Dilling A; Ghoreschi K; Meier K
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e649-e651. PubMed ID: 34169588
    [No Abstract]   [Full Text] [Related]  

  • 4. Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.
    Akoglu G
    Dermatol Ther; 2022 May; 35(5):e15396. PubMed ID: 35187768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate reactions after mRNA SARS-CoV-2 vaccination.
    Jeimy S; Wong T; Song C
    CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
    [No Abstract]   [Full Text] [Related]  

  • 6. De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV.
    Saffarian Z; Samii R; Ghanadan A; Vahidnezhad H
    Dermatol Ther; 2022 Jun; 35(6):e15448. PubMed ID: 35289040
    [No Abstract]   [Full Text] [Related]  

  • 7. Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).
    Li X; Peng K; Cheng FWT; Lam DCL; Cheung CL; Chui CSL; Lai FTT; Wan EYF; Wong CKH; Ma T; Yum SHH; Chan EWY; Huang JD; Lau CS; Ip MSM; Wong ICK
    J Infect; 2023 Mar; 86(3):256-308. PubMed ID: 36539043
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
    Fornaro M; Venerito V; Iannone F; Cacciapaglia F
    J Rheumatol; 2022 Mar; 49(3):334-335. PubMed ID: 35033998
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al.
    Scorza FA; Finsterer J
    Clin Microbiol Infect; 2022 Mar; 28(3):452-453. PubMed ID: 34839005
    [No Abstract]   [Full Text] [Related]  

  • 10. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination.
    Gambichler T; Scholl L; Dickel H; Ocker L; Stranzenbach R
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e415-e416. PubMed ID: 33725406
    [No Abstract]   [Full Text] [Related]  

  • 11. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
    Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
    Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV-2 vaccination.
    Norimatsu Y; Yoshizaki A; Yamada T; Akiyama Y; Toyama S; Sato S
    J Dermatol; 2023 Feb; 50(2):e74-e75. PubMed ID: 35906790
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2.
    Ramot Y; Nanova K; Faitatziadou SM; Assab DA; Berkun Y; Zlotogorski A
    J Dtsch Dermatol Ges; 2022 Aug; 20(8):1123-1124. PubMed ID: 35698860
    [No Abstract]   [Full Text] [Related]  

  • 15. Myocarditis After BNT162b2 and mRNA-1273 Vaccination.
    Larson KF; Ammirati E; Adler ED; Cooper LT; Hong KN; Saponara G; Couri D; Cereda A; Procopio A; Cavalotti C; Oliva F; Sanna T; Ciconte VA; Onyango G; Holmes DR; Borgeson DD
    Circulation; 2021 Aug; 144(6):506-508. PubMed ID: 34133884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
    Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L
    JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection.
    Wolff MJ; Acevedo ML; Núñez MA; Lafourcade M; Gaete-Argel A; Soto-Rifo R; Valiente-Echeverría F
    J Travel Med; 2022 May; 29(3):. PubMed ID: 35134229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [Comirnaty
    Ando M; Satonaga Y; Takaki R; Yabe M; Kan T; Omote E; Yamasaki T; Komiya K; Hiramatsu K
    Int J Infect Dis; 2022 Nov; 124():187-189. PubMed ID: 36122668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.